Next Article in Journal
Functional Imaging in Diagnostic of Orthopedic Implant-Associated Infections
Next Article in Special Issue
Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
Previous Article in Journal
A Multi-Camera System for Bioluminescence Tomography in Preclinical Oncology Research
Previous Article in Special Issue
Computed Tomography (CT) Perfusion in Abdominal Cancer: Technical Aspects
Article

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

1
Peter Gorer Department of Immunobiology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK
2
Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, Copenhagen, 2200, Denmark
3
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark
4
Department of Clinical Pathology, Næstved Hospital, Ringstedgade 61, Naestved, 4700, Denmark
5
Risø National Laboratory, Danish Technical University, Anker Engelunds Vej 1, Lyngby, 2100, Denmark
6
Department of Surgery C, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Diagnostics 2013, 3(4), 344-355; https://doi.org/10.3390/diagnostics3040344
Received: 26 August 2013 / Revised: 11 September 2013 / Accepted: 13 September 2013 / Published: 2 October 2013
(This article belongs to the Collection Feature Papers)
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via somatostatin receptors. Despite promising clinical results, very little is known about the mechanism of tumor control. By using NCI-H727 cells in an in vivo murine xenograft model of human NETs, we showed that 177Lu-DOTATATE PRRT led to increased infiltration of CD86+ antigen presenting cells into tumor tissue. We also found that following treatment with PRRT, there was significantly increased tumor infiltration by CD49b+/FasL+ NK cells potentially capable of tumor killing. Further investigation into the immunomodulatory effects of PRRT will be essential in improving treatment efficacy. View Full-Text
Keywords: PRRT; 177Lu-DOTATATE; CD86+; CD49b+; FasL+; dendritic cells; NK cells PRRT; 177Lu-DOTATATE; CD86+; CD49b+; FasL+; dendritic cells; NK cells
Show Figures

Figure 1

MDPI and ACS Style

Wu, Y.; Pfeifer, A.K.; Myschetzky, R.; Garbyal, R.S.; Rasmussen, P.; Knigge, U.; Bzorek, M.; Kristensen, M.H.; Kjaer, A. Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor. Diagnostics 2013, 3, 344-355. https://doi.org/10.3390/diagnostics3040344

AMA Style

Wu Y, Pfeifer AK, Myschetzky R, Garbyal RS, Rasmussen P, Knigge U, Bzorek M, Kristensen MH, Kjaer A. Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor. Diagnostics. 2013; 3(4):344-355. https://doi.org/10.3390/diagnostics3040344

Chicago/Turabian Style

Wu, Yin, Andreas K. Pfeifer, Rebecca Myschetzky, Rajendra S. Garbyal, Palle Rasmussen, Ulrich Knigge, Michael Bzorek, Michael H. Kristensen, and Andreas Kjaer. 2013. "Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor" Diagnostics 3, no. 4: 344-355. https://doi.org/10.3390/diagnostics3040344

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop